Relay Therapeutics Inc is a biotechnology company that focuses on the discovery and development of new medicines using its innovative platform that integrates computation and experimental approaches. The company was founded in 2016 by a team of experienced researchers and entrepreneurs from leading institutions, including Harvard University, Massachusetts Institute of Technology (MIT), and Vertex Pharmaceuticals.
The primary focus of Relay Therapeutics is to discover and develop small molecule drugs that target protein motion, a fundamental aspect of protein function that was traditionally challenging to study and target with traditional drug discovery methods. The company's platform combines advanced computational techniques with experimental biology to map and understand the dynamic motions of proteins, allowing them to design drugs that interact with these motions and modulate protein function effectively.
Relay Therapeutics seeks to address unmet medical needs in various therapeutic areas, including oncology and genetic diseases. By targeting proteins with greater precision, the company aims to develop transformative therapies that have the potential to significantly impact patient outcomes.
The company has a pipeline of drug candidates in various stages of development, with a particular focus on oncology. Relay's lead drug candidate, RLY-1971, is being evaluated in clinical trials for the treatment of patients with solid tumors, and the company has several other preclinical programs targeting different cancer types and genetic diseases.
Relay Therapeutics' innovative approach to drug discovery and its focus on targeting protein motion have garnered attention and investments from prominent pharmaceutical companies and investors. The company has formed collaborations with leading biopharmaceutical companies, including Sanofi, to advance its drug development efforts.
In addition to its drug discovery efforts, Relay Therapeutics actively collaborates with academic and industry partners to advance the understanding of protein motion and its role in disease biology. The company's commitment to scientific excellence and cutting-edge technology positions it as a promising player in the biotechnology sector with the potential to make significant contributions to the field of drug discovery and personalized medicine.